Wuhan Keqian Biology Co Ltd - Asset Resilience Ratio
Wuhan Keqian Biology Co Ltd (688526) has an Asset Resilience Ratio of 19.42% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 688526 current assets to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2020–2024)
This chart shows how Wuhan Keqian Biology Co Ltd's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Wuhan Keqian Biology Co Ltd (688526) total assets.
Liquid Assets Composition Over Time
This chart breaks down Wuhan Keqian Biology Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read 688526 total liabilities for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥922.80 Million | 19.42% |
| Total Liquid Assets | CN¥922.80 Million | 19.42% |
Asset Resilience Insights
- Good Liquidity Position: Wuhan Keqian Biology Co Ltd maintains a healthy 19.42% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Wuhan Keqian Biology Co Ltd Industry Peers by Asset Resilience Ratio
Compare Wuhan Keqian Biology Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Abivax SA
PA:ABVX |
Biotechnology | 2.58% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Lifecome Biochemistry Co Ltd
SHE:002868 |
Biotechnology | 4.69% |
|
Pulike Biological Engineering
SHG:603566 |
Biotechnology | 17.82% |
|
Rocket Pharmaceuticals Inc
NASDAQ:RCKT |
Biotechnology | 14.00% |
|
NEWRON PHARMACEUT. EO-20
XETRA:NP5 |
Biotechnology | 41.67% |
|
Upstream Bio, Inc.
NASDAQ:UPB |
Biotechnology | 64.70% |
Annual Asset Resilience Ratio for Wuhan Keqian Biology Co Ltd (2020–2024)
The table below shows the annual Asset Resilience Ratio data for Wuhan Keqian Biology Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 16.00% | CN¥719.51 Million ≈ $105.29 Million |
CN¥4.50 Billion ≈ $657.88 Million |
+0.05pp |
| 2023-12-31 | 15.95% | CN¥745.04 Million ≈ $109.02 Million |
CN¥4.67 Billion ≈ $683.55 Million |
+0.58pp |
| 2022-12-31 | 15.37% | CN¥674.83 Million ≈ $98.75 Million |
CN¥4.39 Billion ≈ $642.49 Million |
+9.65pp |
| 2021-12-31 | 5.72% | CN¥212.95 Million ≈ $31.16 Million |
CN¥3.73 Billion ≈ $545.13 Million |
-2.96pp |
| 2020-12-31 | 8.68% | CN¥270.00 Million ≈ $39.51 Million |
CN¥3.11 Billion ≈ $455.23 Million |
-- |
About Wuhan Keqian Biology Co Ltd
Wuhan Keqian Biology Co.,Ltd focuses on the research and development, production, sales, and animal epidemic prevention technical services of veterinary biological products in China. The company offers vaccines for pigs, poultry, and pets, as well as diagnostic reagents. Wuhan Keqian Biology Co.,Ltd was founded in 2001 and is based in Wuhan, China.